Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial - HAL Accéder directement au contenu
Communication dans un congrès Année : 2011

Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial

Loading...
Fichier non déposé

Dates et versions

halshs-00628854, version 1 (04-10-2011)

Identifiants

  • HAL Id : halshs-00628854 , version 1

Citer

Lionel Perrier, Anne Lefranc, Philippe Quittet, Hervé Ghesquières, Bertrand Favier, et al.. Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial. 8th World congress on Health Economics, International Health Economics Association, Toronto, Canada, 10-13 juillet 2011, Jul 2011, Toronto, Canada. ⟨halshs-00628854⟩
189 Consultations
0 Téléchargements
Dernière date de mise à jour le 20/04/2024
comment ces indicateurs sont-ils produits

Partager

Gmail Facebook Twitter LinkedIn Plus